BillionToOne (BLLN)
Financials 
Technical Analysis 
Jul 24, 2026, 12:00 amThis summary was created by AI, based on 1 opinions in the last 12 months.
BillionToOne (BLLN-Q) has made significant strides since its impressive IPO, positioning itself as a leader in the genetic testing sector with technology that surpasses competitors. The company has showcased remarkable growth, as evidenced by a compounded annual sales growth of 167% since 2021, alongside last year's substantial revenue growth of 113%. Their Q3 guidance of revenue growth ranging from 112% to 120% is indicative of their robust market performance. An important financial milestone was reached this year when EBITDA turned positive, showcasing the company's transition to profitability. Despite these positive indicators, experts note that the stock has experienced volatility following a recent pullback, leading some to consider waiting for a more attractive entry point before investing.
- «
- ‹
- 1
- ›
- »
Popular Articles
BillionToOne (BLLN) Frequently Asked Questions
What is BillionToOne stock symbol?
BillionToOne is a OTC stock, trading under the symbol BLLN (previously BLLN-Q on Stockchase) on the undefined (undefined). It is usually referred to as or BLLN
Is BillionToOne a buy or a sell?
In the last year, 1 stock analyst issued a Buy, Sell, or Hold rating on BLLN (previously BLLN-Q on Stockchase). 1 analyst recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is PARTIAL BUY. Read the latest stock experts' ratings for BillionToOne.
Is BillionToOne a good investment or a top pick?
BillionToOne was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for BillionToOne.
Why is BillionToOne stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for BillionToOne.
Is BillionToOne worth watching?
BillionToOne is covered by Stockchase experts and is worth watching.
They had an impressive IPO recently. They make genetic tests to detect diseases early. Their technology is superb and is ahead of their competition. Since 2021, sales have been rising at 167% compounded annually. Last year saw 113% revenue growth. Q3 guidance declared revenue growth at 112-120%. EBITDA turned positive earlier this year. Excellent growth and profitable. Also, they have a clean balance sheet. However, the stock has already seen a pullback, so there's volatility. Wants to see shares fall further to make it more attractive.